| Literature DB >> 20029144 |
S Sudharshan1, Sudha K Ganesh, Jyotirmay Biswas.
Abstract
Posterior uveitic entities are varied entities that are infective or non-infective in etiology. They can affect the adjacent structures such as the retina, vitreous, optic nerve head and retinal blood vessels. Thorough clinical evaluation gives a clue to the diagnosis while ancillary investigations and laboratory tests assist in confirming the diagnosis. Newer evolving techniques in the investigations and management have increased the diagnostic yield. In case of diagnostic dilemma, intraocular fluid evaluation for polymerase chain testing for the genome and antibody testing against the causative agent provide greater diagnostic ability.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20029144 PMCID: PMC2841371 DOI: 10.4103/0301-4738.58470
Source DB: PubMed Journal: Indian J Ophthalmol ISSN: 0301-4738 Impact factor: 1.848
SUN working group classification of uveitis and the primary site of inflammation
| Type | Primary site of inflammation | Includes |
|---|---|---|
| Anterior uveitis | Anterior chamber | Iritis, iridocyclitis, anterior cyclitis |
| Intermediate uveitis | Vitreous | Pars planitis, posterior cyclitis, hyalitis |
| Posterior uveitis | Retina/choroid | Focal, multifocal, diffuse choroiditis, chorioretinitis, retinochoroiditis, retinitis, neuroretinitis |
| Panuveitis | Anterior chamber, vitreous and retina or choroid |
Basic management approach – guidelines
Identify the characteristic/typical fundus picture Confirm with specific investigations Treat the primary cause with appropriate anti-infective agent Use systemic steroids as additional anti-inflammatory therapy Avoid periocular/intravitreal steroids In diagnostic dilemmas, intra-ocular fluid evaluation for antibodies or PCR for identification of genome |
Figure 1Fundus picture showing a typical punched-out macular scar of a healed congenital toxoplasmosis
Figure 2Fundus picture showing a typical “headlight in the fog appearance” in a patient with acquired toxoplasmosis
Other anti-Toxoplasmic drugs
Pyrimethamine (100 mg-1st day, 75 mg-2nd day, 50 mg-3rd day, followed by 25 mg once daily) + Sulfadiazine (4 g daily-divided 6th hourly) for 4–6 weeks Clindamycin[ Trimethoprim+sulphamethoxazol–DS tab–160 mg/800 mg–one tab twice daily for 6 weeks Spiramycin–2 g/day in two divided doses Azithromycin–loading dose 1 G-1st day, followed by 500 mg once daily for 3 weeks Atovaquone[ |
Anti-Toxoplasma therapy in special situations
| Pregnancy | I trimester – Spiramycin + Sulfadiazine |
| II trimester (>14 weeks) – Spiramycin + sulfadiazine + pyrimethamine + folinic acid | |
| III trimester – Spiramycin + pyrimethamine + folinic acid | |
| Newborn | Pyrimethamine, sulfadiazine, and folinic acid |
| Mother | Reduces the likelihood of congenital transmission |
Figure 3Fundus picture showing a toxocara granuloma
Figure 4Fundus picture showing a tuberculous subretinal abscess
Figure 5Fundus picture showing the classical “cracked mud appearance” in progressive outer retinal necrosis
Figure 6Fundus picture showing a typical “pizza pie appearance” in a patient with cytomegalovirus retinitis
Figure 7Fundus picture showing disc edema and macular exudates characteristic of a neuroretinitis
Basic management approach to a case of non-infective posterior uveitis
| Identify the clinical entity based on characteristic clinical feature |
| Rule out infective causes |
| Systemic steroids are the mainstay of therapy |
| Use intravenous methyl prednisolone therapy in vision-threatening lesions |
| Use immunosuppressives, with caution, in recalcitrant cases |
| Monitor side effects of treatment |
Comparative characteristics of clinical presentations of white dot syndrome[52]
| APMPPE | Birdshot | PIC | MEWDS | MFC | GHPC | POHS | |
|---|---|---|---|---|---|---|---|
| Age | Young (20–40) Rarely-children | Middle-aged (40–60) | Middle aged (myopes) | Young (20–40) myopes | Myopic (20–60) | Variable (30–60) | Middle aged |
| Sex | M=F | F>M | F>M | F>M | F>M | M>F | M=F |
| Laterality | Bilateral, asymmetric | Bilateral | Bilateral | Unilateral | Bilateral; asymmetric | Bilateral; asymmetric | Bilateral |
| Viral illness | + | - | + | + | +/- | - | +/- |
| Onset | Abrupt | Insidious | Abrupt | Abrupt | Insidious | Variable | Abrupt |
| Duration | Weeks–months | Chronic | Weeks–months | Weeks–months | Chronic | Chronic | Chronic |
| Recurrence | Rare | Recurrent | Recurrent | Rare | Recurrent | Recurrent | Rare |
| Vitritis | Mild | Moderate with disc edema, CME | Absent | Mild | Moderate and anterior uveitis | Mild | Absent/mild |
| ERG/EOG | Abnormal EOG | Abnormal ERG | Abnormal | Abnormal ERG | Abnormal ERG | Normal | Abnormal |
| HLA | B7, DR2 | A29 | - | - | - | B7 | HLA-DR2 HLA-B7 |
| Fundus - active | Multifocal, flat gray-white placoid lesions primarily-posterior pole at the level of RPE and chorio capillaries | Multiple depigmented yellow-white patches scattered throughout fundus in the postequatorial region. These lesions radiate from optic nerve and follow larger choroidal vessels | Multiple, discrete, flat, yellow, round lesion (50–300 microns) at the level of RPE and inner choroid. Concentrated at posterior pole | Multiple small (100–200 μ), round, slightly indistinct, white/yellow-white spots distributed over posterior fundus, especially at perifoveal and peripapillary regions at the level of RPE | Multiple yellow or gray lesions at the level of choroid and RPE. Mid periphery (50–100 μ) | Macular, peripapillary or ampigenous -irregular, gray-white or cream-yellow subretinal infiltrates at the level of the choriocapillaries and RPE -snake-like pattern | Peripapillary atrophy, atrophic chorioretinal lesions, CNV, punched out yellow lesions Linear streak-smidperiphery |
| Fundus- healed | RPE clumping and hyperpigmentation | Lesions have a hyperpigmented edge but are frequently hypopigmented in the center | Heals rarely by scarring | Punched-out atrophic scars that develop pigmentation over time | Heals from center towards periphery | Scars | |
| Pathogenesis | DTH | Auto immune | - | ?Hormonal | - | Idiopathic/ ?infective | - |
Wks–Weeks, DTH–Delayed type of hypersensitivity
Clue to diagnosis of white dot syndrome
| Characteristics of lesions | Consider |
|---|---|
| Subtle lesions | MEWDS |
| Prominent lesions | MFC |
| Placoid lesions | APMPPE if discrete and if they are coalesced, consider ampigenous or serpiginous choroiditis |
| Discrete lesions | MEWDS, DUSN, MFC, Birdshot chorioretinopathy |
Figure 8Fundus picture showing placoid lesions of acute posterior multifocal placoid pigment epitheliopathy
Figure 9Fundus picture showing active geographic helicoid peripapillary choroidopathy
Comparative characteristics of FFA and ICG features of white dot syndrome[52]
| APMPPE | Birdshot | PIC | MEWDS | MFC | GHPC | POHS | |
|---|---|---|---|---|---|---|---|
| FFA active | Early hypofluorescence and late hyperfluorescence | Mild hyperfluorescence and staining in late phase | Early hypofluorescence and late hyperfluorescence | Early patchy punctate hyperfluorescence with late deep staining of RPE and peripapillary area. Leakage from optic disk and retinal capillaries. Early fluorescence-wreathlike pattern. Choroidal background fluorescence between lesions is normal | Early hypofluorescence and late hyperfluorescence | Early hypofluorescence and late hyperfluorescence. Choroidal vessels are easily seen | Early hypofluorescence and late hyperfluorescence. Confirms CNVM |
| FFA inactive | Window defects | Window defects | Window defects | Window defects | Window defects. Early hyperfluorescence and late staining | Window defects | Window defects |
| ICG-active | Marked choroidal hyperfluorescence in both early and late phase. Large choroidal vessels seen | - | CNVM reveals hyperfluorescence | Multiple hypofluorescent spots in the posterior pole and hyperfluorescence around optic nerve head, especially in patients with enlarged blind spots | Hypofluorescent CNVM reveals hyperfluorescence | - | - |
| ICG-active | Choroidal hypofluorescence | - | - | Hypofluorescent spots persist until patient recovers | Hypofluorescent. | - | - |
| ERG/VEP | - | unilateral negative ERG | - | markedly reduced a wave and early receptor potential amplitudes suggesting primary involvement of RPE | - | - | |
| Visual fields | - | Enlargement of blind spot No correlation of field defects with lesions |